

1 **Nationally representative prevalence and determinants of post-acute**  
2 **sequelae of SARS-CoV-2 infection (Long COVID) amongst Mexican adults in**  
3 **2022**

4 Omar Yaxmehen Bello-Chavolla<sup>1\*</sup>, Carlos A. Fermín-Martínez<sup>1,2\*</sup>, Luisa Fernández-  
5 Chirino<sup>1</sup>, Daniel Ramírez-García<sup>1,3</sup>, Arsenio Vargas-Vázquez<sup>3</sup>, Martín Roberto Basile-  
6 Alvarez<sup>1,3</sup>, Paulina Sánchez Castro<sup>1,3</sup>, Alejandra Núñez-Luna<sup>1,3</sup>, Neftali Eduardo Antonio-  
7 Villa<sup>4</sup>

8 ***\*These authors contributed equally to the drafting of this work***

9

10 <sup>1</sup>Research Division, Instituto Nacional de Geriátría, Mexico City, Mexico. <sup>2</sup>MD/PhD  
11 (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México,  
12 Mexico City, Mexico. <sup>3</sup>Facultad de Medicina, Universidad Nacional Autónoma de México,  
13 Mexico City, Mexico. <sup>4</sup>Department of Endocrinology, Instituto Nacional de Cardiología  
14 Ignacio Chávez, Mexico City, Mexico.

15

16

17

18

19 **Correspondence:**

20 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional de Geriátría.  
21 Anillo Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City,  
22 Mexico. Phone: +52 (55) 5548486885. E-mail: [oyaxbell@yahoo.com.mx](mailto:oyaxbell@yahoo.com.mx)

23

24

25

26 **CONFLICT OF INTERESTS:** The authors declare that they have no conflict of interests.

27 4,049 text words; 44 references; 4 figures, 1 tables.

28 **Running headline:** Long COVID prevalence and determinants in Mexico

29 **ABSTRACT (248 WORDS)**

30 **OBJECTIVE:** To characterize the epidemiology of post-acute sequelae after SARS-CoV-2  
31 infection (PASC) in Mexico during 2022 and identify potential predictors of PASC  
32 prevalence using nationally representative data.

33 **METHODS:** We analyzed data from the 2022 Mexican National Health and Nutrition  
34 Survey (ENSANUT) totaling 24,434 participants, representing 85,521,661 adults  $\geq 20$   
35 years. PASC was defined using both the World Health Organization definition and a PASC  
36 score  $\geq 12$ . Estimates of PASC prevalence were stratified by age, sex, rural vs. urban  
37 setting, social lag quartiles, number of reinfections, vaccination status and by periods of  
38 predominance of SARS-CoV-2 circulating variants. Predictors of PASC were assessed  
39 using logistic regression models adjusted by survey weights.

40 **RESULTS:** Persistent symptoms after SARS-CoV-2 infection were reported by 12.44%  
41 (95%CI 11.89-12.99) of adults  $\geq 20$  years in Mexico during 2022. The most common  
42 persistent symptoms were musculoskeletal pain, headache, cough, loss of smell or taste,  
43 fever, post-exertional malaise, brain fog, anxiety, chest pain, and sleep disorders. PASC  
44 was present in 21.21% (95%CI 7.71-9.65) subjects with previously diagnosed COVID-19.  
45 Over 28.6% patients with PASC reported symptoms persistence  $\geq 6$  months and 14.05%  
46 reported incapacitating symptoms. Higher PASC prevalence was associated with SARS-  
47 CoV-2 reinfections, depressive symptoms and living in states with high social lag. PASC  
48 prevalence, particularly its more severe forms, decreased with COVID-19 vaccination and  
49 for infections during periods of Omicron variant predominance.

50 **CONCLUSIONS:** PASC implies a significant public health burden in Mexico as the  
51 COVID-19 pandemic transitions into endemicity. Promoting reinfection prevention and  
52 booster vaccination may be useful to reduce PASC burden.

53 **Keywords:** Long COVID; PASC; Mexico; COVID-19; sequelae

54

## 55 INTRODUCTION

56 Post-acute persistent symptoms of severe acute coronavirus 2 (SARS-CoV-2) infection  
57 remain a challenge to reduce the burden of SARS-CoV-2 in affected patients as the  
58 coronavirus disease (COVID-19) pandemic progresses towards endemicity (1). The  
59 definition of post-acute sequelae after SARS-CoV-2 infection (PASC) is still evolving given  
60 heterogeneous patient profiles, with other terms also recognizing it as post-acute COVID-  
61 19 condition, long COVID, and post-acute COVID-19 syndrome (2). A Delphi consensus  
62 by the World Health Organization defined it as a condition affecting individuals with  
63 suspected or confirmed SARS-CoV-2 infection exhibiting persistent symptoms lasting for  
64 at least two months without an alternative pathophysiological explanation (3). Recently,  
65 Thaweethai et al. developed a self-reported symptom-based definition to better  
66 characterize persistent COVID-19 symptoms across cohorts and provide another overview  
67 of the epidemiology of PASC (4). To this date, reports on the epidemiology of persistent  
68 symptoms are scarce, particularly in Latin American countries, which hinders recognition  
69 of the magnitude of the problem and implementation of public policies aimed at reducing  
70 PASC burden (5).

71 Mexico is one of the countries with the highest morbidity and mortality related to COVID-19  
72 world-wide (6). A landscape of high cardio-metabolic burden with marked social  
73 inequalities increased the impact of the pandemic and led to sustained excess deaths,  
74 which were ameliorated with the availability of vaccines (7–9). Despite the well-  
75 characterized acute impact of the SARS-CoV-2 pandemic in low- and middle-income  
76 settings, information regarding the impact of debilitating chronic sequelae of SARS-CoV-2  
77 infection in these settings is lacking. In Mexico, few reports have evaluated the impact of  
78 PASC, particularly focusing on cases with severe COVID-19 (10,11). However, nationally  
79 representative estimates of persistent COVID-19 symptoms and particularly PASC as

80 defined by current criteria in Mexico remain unreported. Here, we aimed to estimate the  
81 prevalence of persistent COVID-19 symptoms and post-acute sequelae of SARS-CoV-2  
82 infection (PASC) using a nationally representative sample of Mexican adults for the year  
83 2022. We also aimed to evaluate potential correlates of PASC prevalence including  
84 sociodemographic and infection-related determinants to characterize vulnerable groups  
85 and potential areas of intervention to ameliorate the long-term burden of COVID-19 in  
86 Mexico.

## 87 **METHODS**

### 88 Study design

89 We analyzed data from the Mexican National Health and Nutrition Survey (ENSANUT) for  
90 the year 2022. Briefly, ENSANUT is a population-based survey that aims to assess the  
91 health and nutritional status of Mexican adults. ENSANUT is representative at a national,  
92 regional, and rural/urban level, as it uses two-stage probabilistic cluster stratified sampling  
93 based on households and individuals. Participants underwent a comprehensive  
94 questionnaire collecting demographic, socioeconomic, and health-related data, and a  
95 physical exam including measurement of blood pressure and anthropometry. ENSANUT  
96 2022 was collected from July to December 2022 in 10,160 households (response rate of  
97 73%) which amounts to 11,472 complete interviews in adults  $\geq 20$  years old (12). This  
98 survey additionally aimed to investigate health and well-being of Mexican adults during the  
99 COVID-19 pandemic and a random subsample of 5,971 adults  $\geq 20$  years old provided a  
100 capillary blood sample to detect antibodies for SARS-CoV-2 infection. A second  
101 subsample (n=2,092) had an additional biochemical evaluation with venous blood samples  
102 for glycated hemoglobin (HbA1c), fasting glucose, and a fasting lipid profile. A complete  
103 flowchart of participant selection is outlined in **Supplementary Materials**.

### 104 SARS-CoV-2 seroprevalence

105 Seropositivity to SARS-CoV-2 was evaluated using an Elecsys detection assay for IgG  
106 against the N-protein (SARS-CoV-2 Nucleocapsid, #09 203 079 190, Roche-N) validated  
107 by the Institute for Epidemiological and Diagnostic Reference. Samples were considered  
108 positive if quantification was  $\geq 0.72.0$  U/ml (13). COVID-19 seroprevalence was estimated  
109 using population sample weights with the *survey* R package.

#### 110 Variable definitions

##### 111 *Persistent COVID-19 symptoms*

112 Previously diagnosed COVID-19 was defined by self-report among individuals who  
113 answered, “at least once” to the question: “Since February 2020, how many times have  
114 you been diagnosed with COVID-19 by health personnel?” Amongst individuals with at  
115 least one previous COVID-19 diagnosis, persistent symptoms after SARS-CoV-2 infection  
116 were asked (3) using the question: “Regarding the last time you had COVID, did you  
117 continue to present any of these symptoms / sequelae one month after your illness  
118 began?” and interrogated the presence of the following symptoms: cough, fatigue or  
119 tiredness, anxiety, depression, fever, difficulty sleeping, kidney complications, loss of  
120 appetite, weight loss, headache, dizziness, muscle or joint pain, difficulty breathing  
121 (dyspnea), shortness of breath, chest pain, vomiting or diarrhea (gastrointestinal  
122 symptoms), loss or decrease in smell, loss or decrease in taste, difficulty thinking or  
123 concentrating or other symptoms, including post-exertional malaise, which we defined as  
124 symptoms which worsen with activity and impede normal functioning. Participants were  
125 also asked to clarify if the symptoms persisted for less than an additional month, from one  
126 to three months, from three to six months, more than 6 months, or are still present.

##### 127 *Post-acute COVID-19 sequelae*

128 We used the definition reached by Delphi consensus from the World Health Organization,  
129 which defines PASC, which defines it as the presence of at least one persistent symptom,

130 in individuals with previously diagnosed SARS-CoV-2 infection, and which referred  
131 persistent symptoms lasting  $\geq 3$  months from the previous COVID-19 diagnosis. Based on  
132 this, we classified persistent symptoms into subacute or ongoing symptomatic COVID-19,  
133 defined as the presence of any persistent symptom 4-12 weeks beyond acute COVID-19  
134 and PASC(14). Furthermore, based on a recent definition by Thaweethai et al. we  
135 calculated the PASC score, which defined the presence of PASC with a score  $\geq 12$  points  
136 to assess its prevalence in this population (4). Symptoms such as palpitations, chronic  
137 thirst, decreased sexual desire or capacity, or abnormal movements were not considered  
138 in ENSANUT 2022 and were not included for score calculation. This complementary  
139 definition was included as a sensitivity analysis and was considered irrespective of  
140 symptom duration.

#### 141 *Modifying factors*

142 We evaluated age categories of 10-year intervals (20-29, 30-39, 40-49, 50-59, 60-69 or  
143  $\geq 70$  years), sex, rural/urban area, smoking status and presence of diabetes and  
144 hypertension as modifying factors of PASC prevalence. The following factors were also  
145 considered to evaluate components of SARS-CoV-2 infection:

- 146 • **SARS-CoV-2 reinfection** – Defined as having been diagnosed with COVID-19  
147 more than one time by healthcare personnel (self-report).
- 148 • **Predominant SARS-CoV-2 variants** – SARS-CoV-2 infection was assumed to be  
149 most likely caused by the predominant variant based on the date of symptom  
150 onset. Based on data submitted to GISAID (48), from March 3rd, 2020, until  
151 December 30th, 2020, the predominant SARS-CoV-2 variant was the ancestral  
152 strain, followed by the predominance of the B.1.1.519 variant until June 6th, 2021,  
153 the B.1.617.2 (Delta) variant until December 6th, 2021. B.1.1.529.1 (Omicron)  
154 subvariant was considered predominant from December 7th, 2022, onwards (15).

155 For modeling, COVID-19 were classified into those likely caused by the Omicron  
156 variant or otherwise.

157 • **COVID-19 vaccination** – Vaccination was defined by self-report among individuals  
158 who answered “yes” to the question: “Have you been vaccinated for COVID-19?”  
159 and further questioned if receiving one, two, three or four vaccine doses.

160 • **Social lag** – We used data from the National Council for Evaluation of Social  
161 Development Policy (CONEVAL), which provides state-level estimates of the 2020  
162 social lag index (SLI), which is a composite measure of access to education, health  
163 care, dwelling quality, and basic services in Mexico (16). To assess marginalization  
164 independently of urbanization, we extracted mean population density from each  
165 state and regressed it onto SLI and obtained the residuals which represent a  
166 density-independent social lag index (DISLI) (9,17,18). We then categorized states  
167 into DISLI quartiles (Q1-Q4) and classified individuals from each quartile to each  
168 according to their state of residence.

169 • **Depressive symptoms** – Evaluated using the seven-item version of the Center for  
170 Epidemiologic Studies Depression Scale (CESD-7). CESD-7 measures the  
171 frequency with which depressive symptoms are experienced during the week prior  
172 to the interview collected at ENSANUT 2022. Cut-offs to identify the presence of  
173 moderate or severe depressive symptoms were  $\geq 9$  points for adults aged 20-59,  
174 and  $\geq 5$  points for adults  $\geq 60$  years (19,20).

175 • **Incapacitating symptoms** – Defined if the person answered “yes” to the question  
176 “Do these [persistent COVID-19] symptoms prevent you or did they prevent you  
177 from taking care of yourself? For example, that difficulties to bathe or dress  
178 oneself”.

179 Statistical analyses



180 *Weighted prevalence of PASC and persistent COVID-19 symptoms*

181 Prevalence of PASC and persistent symptoms were estimated using sample weights from  
182 ENSANUT for participants  $\geq 20$  years, as well as those with SARS-CoV-2 seropositivity  
183 and for the population with previously diagnosed COVID-19; all estimations were  
184 conducted using the *survey* R package (21). We further performed weighted subgroup  
185 estimation for prevalence trends stratified by age category, sex, geographical region,  
186 previous reinfection, vaccination status, infection during periods of Omicron variant  
187 predominance, indigenous identity, rural or urban area, and DISLI category (high or  
188 low/middle).

189 *Predictors of PASC prevalence*

190 To identify correlates of PASC positivity we fitted fixed effects logistic regression models  
191 considering survey weights amongst individuals with previously diagnosed COVID-19 and  
192 complete data including comorbidities. A sensitivity analysis was conducted exploring  
193 predictors for any sequelae present compared to the PASC definition. All statistical  
194 analyses were conducted using R version 4.1.2 and p-values thresholds are estimated for  
195 a two-sided significance level of  $\alpha = 0.05$ .

196 **RESULTS**

197 *Study population*

198 We included adults aged  $\geq 20$  years old who completed the health questionnaire, totaling  
199 24,434 participants (expanded to 85,521,661 adults); amongst them, 4,898 participants  
200 were selected for capilar blood sampling to estimate SARS-CoV-2 seropositivity  
201 (expanded to 85,098,924 adults). A flowchart diagram detailing the participant selection  
202 process is available in **Supplementary Figure 1**. Overall, we identified a prevalence of  
203 previously diagnosed COVID-19 amongst adults  $\geq 20$  years of 22.0% (95%CI 21.31-22.69),  
204 which contrasted markedly with the seroprevalence of IgG against the N-protein of SARS-

205 CoV-2, estimated at 93.66% (95%CI 92.78-94.54). Overall, approximately 86.21% (95%CI  
206 85.64-86.78) of adults had received at least one dose of COVID-19 vaccines, with 11.62%  
207 (95%CI 11.1-12.14) receiving only one dose, 29.6% (95%CI 28.83-30.37) with two doses,  
208 39.51% (95%CI 38.73-40.29) with three doses and 5.48% (95%CI 5.11-5.85) with four  
209 doses.

### 210 Prevalence of persistent COVID-19 symptoms

211 Overall, we identified that 12.44% (95%CI 11.89-12.99) of adults  $\geq 20$  years had at least  
212 one persistent COVID-19 symptom for  $\geq 1$  month, which equates to a total of 10,634,663  
213 individuals (95%CI 10,155,424-11,113,902). Amongst them, 45.87% (95%CI 43.49-48.25)  
214 lasted  $< 1$  additional month, 16.74% (95%CI 14.93-18.55) persisted between 1-3 months,  
215 4.54% (95%CI 3.56 -5.52) between 3-6 months, 4.26% (95%CI 3.28-5.24) for  $> 6$  months  
216 and 28.6% (95%CI 26.43-30.77) persisting until the date of the interview. The prevalence  
217 of any persistent symptoms was similar when analyzing only N-protein seropositive adults  
218 (12.7%, 95%CI 11.48-14.06) and was higher when considering only cases with previously  
219 diagnosed COVID-19 by a physician (56.52%, 95%CI 54.75-58.29). The ten most frequent  
220 persistent symptoms amongst subjects with SARS-CoV-2 N-protein seropositivity were  
221 musculoskeletal pain, headache, cough, loss of smell or taste, fever, post-exertional  
222 malaise, brain fog, anxiety, chest pain, and sleep disorders (**Supplementary Material**).

### 223 Persistent symptoms in selected subgroups

224 Amongst SARS-CoV-2 N-protein seropositive individuals subacute or ongoing  
225 symptomatic COVID-19 was present in 7.42% (95%CI 6.42-8.42), whilst PASC was  
226 present in 5.51% (95%CI 4.61-6.41) of cases (**Figure 1**). The five most common persistent  
227 symptoms in subacute COVID-19 were cough, headache, fever, musculoskeletal pain, and  
228 loss of smell or taste, whilst for PASC they were musculoskeletal pain, post-exertional  
229 malaise, headache, cough, and dyspnea (**Figure 1A-B**). Regarding sex, the prevalence of

230 any persistent symptom amongst SARS-CoV-2 N-protein seropositive individuals was  
231 higher for males (14.12%, 95%CI 12.42-15.85) compared to females (10.50%, 95%CI  
232 8.56-12.44); in males the five most frequent persistent symptoms were headache,  
233 musculoskeletal pain, and cough, whilst for females they were cough, musculoskeletal  
234 pain, and fever (**Supplementary Material**). In cases with previously diagnosed COVID-19  
235 SARS-CoV-2 primoinfection was associated with lower prevalence of persistent sequelae  
236 (55.39%, 95%CI 53.49-57.29) compared to cases with at least one SARS-CoV-2  
237 reinfection (64.41%, 95%CI 59.69-69.13); in cases with SARS-CoV-2 primoinfection the  
238 most common persistent symptoms were musculoskeletal pain, headache, cough, post-  
239 exertional malaise, and loss of smell or taste, whilst for reinfection they were cough,  
240 headache, post-exertional malaise, musculoskeletal pain, and fever (**Supplementary**  
241 **Material**).

#### 242 Prevalence of PASC in Mexico

243 Using the WHO definition, we identified a prevalence of 4.67% (95%CI 4.32-5.02) in the  
244 overall population, 5.51% (95%CI 4.61-6.41) amongst SARS-CoV-2 N-protein seropositive  
245 population, and 21.21% (95%CI 19.74-22.68) in subjects with previously diagnosed  
246 COVID-19, totaling 3,990,011 affected adults (95%CI 3,685,878-4,294,144;  
247 **Supplementary Material**). We identified the highest prevalence of PASC amongst  
248 subjects with previously diagnosed COVID-19 in Mexico City/Mexico State and the  
249 Peninsula region, whilst the lowest prevalence was observed in the US Border region,  
250 coincidentally most clustering in Northern Mexico (**Figure 2A**). When comparing  
251 characteristics between individuals with and without PASC, we identified that individuals  
252 with PASC clustered most persistent symptoms, even those not included in the PASC  
253 score; furthermore, higher rates of reinfections, diabetes and hypertension were observed  
254 individuals with PASC (**Table 1**). Overall, 15.13% (95%CI 13.50-16.76) of individuals

255 affected by persistent symptoms reported incapacity to perform everyday tasks including  
256 take care of oneself; this rate was 14.06% (95%CI 11.37-16.75) amongst PASC compared  
257 to 7.13% (95%CI 6.17-8.09) in individuals without PASC who had previously diagnosed  
258 with COVID-19, indicating a high burden of PASC on everyday functioning. Finally, we  
259 analyzed cases with PASC score  $\geq 12$ , observing a prevalence of 1.91% (95%CI 1.69-  
260 2.13) in the general population, 2.02% (95%CI 1.48-2.56) in SARS-CoV-2 N-protein  
261 seropositive individuals and 8.68% (95%CI 7.72-9.65) in individuals with previously  
262 diagnosed SARS-CoV-2 infection. Notably, incapacitating PASC symptoms were observed  
263 in 45.38% (95%CI 39.65-51.11) of subjects with PASC score  $\geq 12$ , indicating a more  
264 severe phenotype. Furthermore, comparing PASC positive (score  $\geq 12$ ) vs. PASC  
265 indeterminate subjects (score  $< 12$ ) reinfection rates and symptom clustering occurred  
266 most frequently in PASC positive subjects (**Supplementary Material**); interestingly, lower  
267 vaccination and infections detected during periods of Omicron variant predominance were  
268 observed in PASC positive vs. PASC indeterminate individuals. This indicated that the  
269 PASC score likely detected individuals with a more severe PASC phenotype.

#### 270 PASC prevalence in selected subgroups

271 PASC prevalence estimates generally increased with age and were higher in females  
272 compared to males (**Figure 2B**); furthermore, PASC prevalence was higher with  
273 increasing DISLI values, particularly in urban settings (**Figure 2D**). For infection-related  
274 variables the prevalence of PASC was lower if the last infection occurred during periods of  
275 high Omicron variant circulation compared to other SARS-CoV-2 variants and was  
276 generally lower in vaccinated subjects irrespective of variant predominance (**Figure 2C**);  
277 similarly, prevalence of PASC was higher in subjects with at least one reinfection  
278 compared to primoinfection, but this was more evident in cases where COVID-19 was  
279 acquired during periods of Omicron variant predominance (**Figure 2E**). Finally, when

280 evaluating PASC prevalence per year at which the last SARS-CoV-2 infection was  
281 diagnosed, prevalence changed from 25.82% (95%CI 22.40-29.24) for cases infected in  
282 2020, to 21.96% for cases infected in 2021 (95%CI 19.65-24.27), and to 17.60% (95%CI  
283 15.36-19.84) for cases infected in 2022 (**Supplementary Material**).

#### 284 Modifiers of PASC prevalence

285 We fitted fixed effects logistic regression model considering survey weights to identify  
286 correlates of PASC positivity amongst individuals with previously diagnosed COVID-19  
287 and complete data including comorbidities (n=2,504). We identified that infection during  
288 periods of Omicron variant predominance (OR 0.73, 95%CI 0.59-0.90) and male sex (OR  
289 0.75, 95%CI 0.61-0.91) were associated with lower odds of PASC positivity. In addition,  
290 having had at least one SARS-CoV-2 reinfection (OR 1.83, 95%CI 1.38-2.41), having  
291 moderate to severe depressive symptoms as identified by CES-D (OR 1.89, 95%CI 1.51-  
292 2.36), older age, and living in states with higher social lag (OR 1.48, 95%CI 1.10-1.99 for  
293 Q4 vs Q1) were associated with higher odds of PASC positivity (**Figure 3A**). When  
294 evaluating the same predictors but using the definition of PASC score  $\geq 12$  points, which  
295 likely indicates a more severe PASC phenotype, infection during periods of Omicron  
296 variant predominance, COVID-19 vaccination, having had at least one SARS-CoV-2  
297 reinfection, living in states with higher social lag, and moderate to severe depressive  
298 symptoms by CES-D were associated with the outcome (**Figure 3B**); further  
299 disaggregating by the number of vaccine doses compared to unvaccinated individuals  
300 showed a similar protective effect with increasing doses and irrespective of vaccine  
301 platform for primary vaccination schedule (**Supplementary Material**).

#### 302 Predictors of incapacitating PASC symptoms

303 Amongst individuals with persistent symptoms a PASC score  $\geq 12$  points resulted in higher  
304 rates of incapacitating symptoms at all time points and independent of the WHO PASC

305 definition (**Figure 4A**). Predictors of incapacitating symptoms included previously  
306 diagnosed diabetes (OR 1.98, 95%CI 1.00-3.90), moderate to severe depressive  
307 symptoms (OR 1.85, 95%CI 1.07-3.20), age 50-59 years compared to younger individuals  
308 (OR 3.39, 95%CI 1.32-10.37), having had at least one SARS-CoV-2 reinfection (OR 2.58,  
309 95%CI 1.24-5.31) and a lower risk observed in individuals infected during periods of  
310 Omicron variant predominance (OR 0.42, 95%CI 0.22-0.79). Notably, the most significant  
311 predictor of incapacitating PASC symptoms was a PASC score  $\geq 12$  points (OR 4.92,  
312 95%CI 2.37, 10.12).

### 313 **DISCUSSION**

314 Here, we conducted the first comprehensive report on the prevalence of PASC in Mexican  
315 adults during the year 2022, surveying a total of 24,434 participants. Persistent COVID-19  
316 symptoms were reported by 12.44% of adults  $\geq 20$  years in Mexico and amongst 12.7% of  
317 adults with SARS-CoV-2 N-protein seropositivity during 2022. The most commonly  
318 reported persistent COVID-19 symptoms amongst SARS-CoV-2 N-protein seropositive  
319 adults include musculoskeletal pain, followed by headache, cough, loss of smell or taste,  
320 fever, post-exertional malaise, brain fog, anxiety, chest pain, and sleep disorders. Using a  
321 recent the WHO PASC definition (3) we identified a prevalence of 5.51% amongst SARS-  
322 CoV-2 N-protein seropositive Mexican adults and 21.21% amongst cases with previously  
323 diagnosed COVID-19; the prevalence of PASC increased with age and was higher for  
324 females, for SARS-CoV-2 infections detected in 2020 and in settings with higher social lag  
325 in urban settings. PASC was associated with increasing number of SARS-CoV-2  
326 reinfections, moderate to severe depressive symptoms and living in states burdened by  
327 sociodemographic inequalities. We also confirm previous reports that COVID-19  
328 vaccination and infection during periods of Omicron variant predominance decreases odds  
329 of severe forms of PASC (2,22,23). Notably, over 28.6% patients with PASC reported

330 persistence of symptoms over 6 months and over 14.06% reported incapacitating  
331 symptoms, which indicate a subset of participants in whom interventions may lead to a  
332 significant improvement in quality of life (24). Finally, we identified that incapacitating  
333 PASC symptoms were associated with diabetes, moderate to severe depressive  
334 symptoms, SARS-CoV-2 reinfections and a PASC score  $\geq 12$  points. Our study represents  
335 the first comprehensive and nationally representative report of PASC in Mexican adults  
336 and the first report on the impact of vaccination, SARS-CoV-2 variants, reinfections, and  
337 sociodemographic inequalities in the prevalence of PASC and symptom persistence and  
338 severity in Mexico.

339 A previous systematic review identified that approximately 72.5% of individuals previously  
340 infected by SARS-CoV-2 experienced post-acute sequelae (25). This contrasts with a  
341 lower reported prevalence of 56.52% amongst individuals with previously diagnosed  
342 COVID-19 reported in our study and with the even lower estimate amongst SARS-CoV-2  
343 seropositive adults. A previous study using data from ENSANUT 2020 reported that  
344 amongst SARS-CoV-2 seropositive individuals who recovered from COVID-19 in Mexico,  
345 approximately 15.7% reported unspecified sequelae, with these being higher in females,  
346 older adults and hospitalized individuals (11). In our study, we identified that the main  
347 predictors of higher PASC prevalence include SARS-CoV-2 reinfections, moderate to  
348 severe depressive symptoms and sociodemographic inequalities as proxied by the DISLI.  
349 Similar to our findings, previous reports from the UK showed that individuals with PASC  
350 clustered in areas of higher socioeconomic deprivation (26), supporting the notion that  
351 structural determinants of health may influence the incidence and natural history of chronic  
352 debilitating diseases including chronic fatigue syndrome, myalgic encephalitis and PASC  
353 (27,28), as it does during the acute phase of SARS-CoV-2 infection (9). Our findings are  
354 also in agreement with previous data supporting that SARS-CoV-2 reinfections increased

355 the risk of SARS-CoV-2 sequelae, irrespective of predominant variant; although, lower risk  
356 of PASC has been consistently associated with infections caused by the Omicron  
357 compared to previous circulating variants (29,30). Finally, the higher rate of moderate to  
358 severe depressive symptoms and self-reported anxiety in PASC indicates a relevant area  
359 of intervention for affected individuals, particularly since long-term neuropsychiatric  
360 sequelae has been consistently reported in SARS-CoV-2 convalescent individuals after  
361 recovery from acute infection (4,14,31–33).

362 The precise nature behind the pathophysiology of PASC is unclear. Current evidence  
363 suggests involvement of SARS-CoV-2 mediated pathophysiological changes in several  
364 tissues, immune system dysregulation and immune response viral particle persistence and  
365 expected sequelae of critical illness. Increased inflammatory responses and an inadequate  
366 adaptation of the hypothalamic–pituitary–adrenal axis to hypocortisolemia after acute  
367 SARS-CoV-2 infection may underlie the occurrence of symptoms related to brain fog, post-  
368 exertional malaise, and neuropsychiatric symptoms, including anxiety and depression in  
369 PASC positive patients (2,34–36), which often last the longest in patients with persistent  
370 COVID-19 symptoms (10,37). Consistent with findings from our study, previous data has  
371 shown that COVID-19 vaccination decreases the risk of PASC and persistent COVID-19  
372 sequelae (23,38); the mechanism underlying this association is unclear. A previous  
373 immune phenotyping study of PASC identified increased levels of anti-N and anti-S IgG in  
374 individuals with PASC compared to vaccinated controls, indicating persistent chronic  
375 immune responses to SARS-CoV-2 viral antigens in PASC, which may be modulated in  
376 response to COVID-19 vaccination (34). In agreement with our findings for severe PASC  
377 phenotypes, longitudinal evaluations have shown that increasing number of COVID-19  
378 vaccine doses are associated with symptom improvement over time (1,39); however,  
379 some studies have suggested that a subset of participants may not experience



380 improvement or may even experience worsening of symptoms after vaccination (40).  
381 Further evidence is required to investigate the impact of COVID-19 vaccinations after  
382 reinfections, which have been shown to be reduced themselves by booster vaccination  
383 (15).  
384 Our study had several strengths including a nationally representative sample of individuals  
385 with antibody measurement to detect SARS-CoV-2 N-protein seropositivity, previously  
386 diagnosed COVID-19 and reports of long-term sequelae. Furthermore, we were able to  
387 assess risk factors related to state-level sociodemographic inequalities, vaccination,  
388 reinfection, and predominant variant at the time of infection to explore correlates of PASC  
389 in a representative sample of Mexican adults. However, some limitations must be  
390 acknowledged to adequately interpret our results. Since the definition of PASC is still  
391 evolving, we applied two main definitions based on the World Health organization  
392 consensus and a recent definition based on a symptom score (3,4). Despite the  
393 robustness of incorporating several definitions of PASC, we were unable to include all  
394 symptoms evaluated in the PASC score and symptoms and post-COVID-19 conditions  
395 reported in other studies including palpitations, chronic thirst, decreased sexual desire or  
396 capacity, abnormal movements, new-onset diabetes, and cardiovascular events including  
397 coagulopathy and thrombosis, some of which have previously been reported for cases  
398 recovered from severe COVID-19 in Mexico (10); this may lead to an underestimation in  
399 the prevalence of severe PASC using this measure and its impact on patients' health.  
400 Next, we used SARS-CoV-2 N-protein seropositivity as a proxy of previous SARS-CoV-2  
401 infection given the high rates of undetected asymptomatic SARS-CoV-2 infections in  
402 Mexico, which may otherwise lead to an underestimation of PASC prevalence (41,42).  
403 However, a subset of participants who received the CoronaVac inactivated virus vaccine  
404 may display seropositivity despite not having been previously infected, this represents

405 9.44% (95%CI 10.63-11.97) of the total SARS-CoV-2 N-protein seropositive population  
406 (43,44). To address this, we also conducted an analysis excluding individuals who  
407 received with CoronaVac and individuals who had COVID-19 previously diagnosed by a  
408 physician, obtaining largely similar results with slightly lower prevalence estimates  
409 (**Supplementary Material**). Finally, although the observed associations are consistent  
410 with data from previous studies, its observational nature precludes from making temporal  
411 associations with the incidence of PASC, which require further studies to further support  
412 these findings in Mexican population.

### 413 **Conclusion**

414 We report a prevalence of PASC of 4.67% in the general population, affecting 21.21% of  
415 individuals with previously diagnosed COVID-19. In general, over 12.44% of Mexican  
416 adults report at least one persistent COVID-19 symptom, with the most common being  
417 musculoskeletal pain, headache, cough, loss of smell or taste, and fever. PASC  
418 prevalence increased with age and was more common in females; severe PASC was less  
419 frequent for cases infected during periods of Omicron variant predominance and in  
420 vaccinated individuals in a dose-dependent manner but was more common in individuals  
421 with at least one detected SARS-CoV-2 reinfection. Moreover, prevalence of PASC  
422 increased in states with higher marginalization, particularly in urban settings. Of note, over  
423 14.05% of participants affected by PASC reported trouble in everyday physical functioning,  
424 highlighting the disabling nature of persistent symptoms and indicating a need to  
425 implement multidisciplinary teams for patient treatment in Mexico. Further studies are  
426 required to characterize the epidemiology of PASC in Mexico using standardized  
427 definitions and with longer follow-up in order to identify strategies to mitigate its long-term  
428 impact in physical functioning and quality of life as SARS-CoV-2 transitions into  
429 endemicity.

430

431 **ACKNOWLEDGMENTS**

432 CAFM is enrolled at the PECEM Program of the Faculty of Medicine at UNAM. CAFM and  
433 DRG are supported by CONACyT.

434 **AUTHOR CONTRIBUTIONS**

435 Research idea and study design: OYBC, CAFM; data acquisition and processing: CAFM,  
436 NEAV, OYBC; statistical analysis: OYBC; analysis/interpretation: CDPC, CAFM, OYBC,  
437 NEAV, AVV, LFC, DRG; manuscript drafting: OYBC, CAFM, DRG, LFC, AVV, MRBA,  
438 PSC, ANL, NEAV; supervision or mentorship: OYBC, NEAV. Each author contributed  
439 important intellectual content during manuscript drafting or revision and accepts  
440 accountability for the overall work by ensuring that questions pertaining to the accuracy or  
441 integrity of any portion of the work are appropriately investigated and resolved.

442 **DATA AVAILABILITY:** All code, datasets and materials are available for reproducibility of  
443 results at [http://github.com/oyaxbell/pasc\\_ensanut/](http://github.com/oyaxbell/pasc_ensanut/). ENSANUT 2022 data is openly  
444 available at: <https://ensanut.insp.mx/encuestas/ensanutcontinua2022/descargas.php>

445 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

446 **FUNDING:** This research was supported by Instituto Nacional de Geriatria in Mexico.

447

448

449 **REFERENCES**

- 450 1. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings,  
451 mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133–46.
- 452 2. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al.  
453 Attributes and predictors of long COVID. Nat Med. 2021 Apr;27(4):626–31.
- 454 3. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case

- 455 Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-  
456 COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. 2022 Apr;22(4):e102–7.
- 457 4. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al.  
458 Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023  
459 Jun 13;329(22):1934–46.
- 460 5. Sakhamuri SM, Jankie S, Pereira LMP. Calling on Latin America and the  
461 Caribbean countries to recognise the disability from long COVID. *The Lancet Regional*  
462 *Health – Americas* [Internet]. 2022 Nov 1 [cited 2023 Jul 4];15. Available from:  
463 [https://www.thelancet.com/journals/lanam/article/PIIS2667-193X\(22\)00179-X/fulltext](https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00179-X/fulltext)
- 464 6. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al.  
465 Coronavirus Pandemic (COVID-19). *Our World in Data* [Internet]. 2020 Mar 5 [cited 2023  
466 Jul 4]; Available from: <https://ourworldindata.org/coronavirus/country/mexico>
- 467 7. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A,  
468 González-Díaz A, Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-2: A  
469 Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. *The*  
470 *Journal of Clinical Endocrinology & Metabolism*. 2020 Aug 1;105(8):2752–61.
- 471 8. Bello-Chavolla OY, Antonio-Villa NE, Valdés-Ferrer SI, Fermín-Martínez CA,  
472 Fernández-Chirino L, Vargas-Vázquez A, et al. Effectiveness of a nationwide COVID-19  
473 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and  
474 death: a retrospective analysis of national surveillance data. *Int J Infect Dis*. 2023  
475 Apr;129:188–96.
- 476 9. Antonio-Villa NE, Fernandez-Chirino L, Pisanty-Alatorre J, Mancilla-Galindo J,  
477 Kammar-García A, Vargas-Vázquez A, et al. Comprehensive evaluation of the impact of  
478 sociodemographic inequalities on adverse outcomes and excess mortality during the  
479 COVID-19 pandemic in Mexico City. *Clin Infect Dis*. 2021 Jun 22;ciab577.

- 480 10. Núñez I, Gillard J, Fragoso-Saavedra S, Feyaerts D, Islas-Weinstein L, Gallegos-  
481 Guzmán AA, et al. Longitudinal Clinical Phenotyping of Post COVID Condition in Mexican  
482 Patients Recovering from Severe COVID-19: A Prospective Cohort Study [Internet].  
483 Rochester, NY; 2022 [cited 2023 Jul 4]. Available from:  
484 <https://papers.ssrn.com/abstract=4238650>
- 485 11. Vidaña-Pérez D, López-Olmedo N, González-Morales R, Shamah-Levy T,  
486 Barrientos-Gutiérrez T. Prevalence of Covid-19 sequelae in the National Health and  
487 Nutrition Survey 2020. *Salud Pública de México*. 2021 Oct 25;63(6, Nov-Dic):799–802.
- 488 12. Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arrendondo  
489 S, Colchero MA, Gaona-Pineda EB, et al. Metodología de la Encuesta Nacional de Salud  
490 y Nutrición 2022 y Planeación y diseño de la Ensanut Continua 2020-2024. *Salud Pública*  
491 *de México*. 2022 Aug 26;64(5, sept-oct):522–9.
- 492 13. Sánchez-Pájaro A, Ferrer CP, Basto-Abreu A, Rivera-Dommarco J, Barquera S,  
493 Denova-Gutiérrez E, et al. Seroprevalencia de SARS-CoV-2 en adultos y adultos mayores  
494 en México y su asociación con enfermedades crónicas. *Ensanut 2020 Covid-19*. *Salud*  
495 *Pública de México*. 2021 Nov 5;63(6, Nov-Dic):705–12.
- 496 14. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.  
497 Post-acute COVID-19 syndrome. *Nat Med*. 2021 Apr;27(4):601–15.
- 498 15. Montes-González JA, Zaragoza-Jiménez CA, Antonio-Villa NE, Fermín-Martínez  
499 CA, Ramírez-García D, Vargas-Vázquez A, et al. Protection of hybrid immunity against  
500 SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant  
501 predominance in Mexico. *Front Public Health*. 2023;11:1146059.
- 502 16. Índice Rezago Social 2020 [Internet]. [cited 2023 Jul 1]. Available from:  
503 [https://www.coneval.org.mx/Medicion/IRS/Paginas/Indice\\_Rezago\\_Social\\_2020.aspx](https://www.coneval.org.mx/Medicion/IRS/Paginas/Indice_Rezago_Social_2020.aspx)
- 504 17. Antonio-Villa NE, Bello-Chavolla OY, Fermín-Martínez CA, Aburto JM, Fernández-

- 505 Chirino L, Ramírez-García D, et al. Socio-demographic inequalities and excess non-  
506 COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174  
507 death certificates in Mexico. *Int J Epidemiol.* 2022 Dec 13;51(6):1711–21.
- 508 18. Bello-Chavolla OY, Antonio-Villa NE, Fermín-Martínez CA, Fernández-Chirino L,  
509 Vargas-Vázquez A, Ramírez-García D, et al. Diabetes-Related Excess Mortality in Mexico:  
510 A Comparative Analysis of National Death Registries Between 2017–2019 and 2020.  
511 *Diabetes Care.* 2022 Oct 26;45(12):2957–66.
- 512 19. Salinas-Rodríguez A, Manrique-Espinoza B, Acosta-Castillo GI, Franco-Núñez A,  
513 Rosas-Carrasco O, Gutiérrez-Robledo LM, et al. [Validation of a cutoff point for the short  
514 version of the Depression Scale of the Center for Epidemiologic Studies in older Mexican  
515 adults]. *Salud Publica Mex.* 2014;56(3):279–85.
- 516 20. Salinas-Rodríguez A, Manrique-Espinoza B, Acosta-Castillo I, Téllez-Rojo MM,  
517 Franco-Núñez A, Gutiérrez-Robledo LM, et al. [Validation of a cutoff for the Depression  
518 Scale of the Center for Epidemiologic Studies, Brief Version (CESD-7)]. *Salud Publica*  
519 *Mex.* 2013;55(3):267–74.
- 520 21. survey.pdf [Internet]. [cited 2023 Apr 21]. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/survey/survey.pdf)  
521 [project.org/web/packages/survey/survey.pdf](https://cran.r-project.org/web/packages/survey/survey.pdf)
- 522 22. Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19  
523 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation  
524 Using Data From the ComPaRe e-Cohort in France [Internet]. Rochester, NY: Social  
525 Science Research Network; 2021 Sep [cited 2021 Oct 7]. Report No.: ID 3932953.  
526 Available from: <https://papers.ssrn.com/abstract=3932953>
- 527 23. Brannock MD, Chew RF, Preiss AJ, Hadley EC, Redfield S, McMurry JA, et al.  
528 Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the  
529 RECOVER program. *Nat Commun.* 2023 May 22;14(1):2914.

- 530 24. Ballouz T, Menges D, Anagnostopoulos A, Domenghino A, Aschmann HE, Frei A,  
531 et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection:  
532 population based, longitudinal cohort study. *BMJ*. 2023 May 31;381:e074425.
- 533 25. Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of  
534 Persistent Symptoms Among Patients With COVID-19: A Systematic Review. *JAMA Netw*  
535 *Open*. 2021 May 3;4(5):e2111417.
- 536 26. Shabnam S, Razieh C, Dambha-Miller H, Yates T, Gillies C, Chudasama YV, et al.  
537 Socioeconomic inequalities of Long COVID: a retrospective population-based cohort study  
538 in the United Kingdom. *J R Soc Med*. 2023 May 10;1410768231168377.
- 539 27. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Trends in the incidence of  
540 chronic fatigue syndrome and fibromyalgia in the UK, 2001-2013: a Clinical Practice  
541 Research Datalink study. *J R Soc Med*. 2017 Jun;110(6):231–44.
- 542 28. BERGER Z, ALTIERY DE JESUS V, ASSOUMOU SA, GREENHALGH T. Long  
543 COVID and Health Inequities: The Role of Primary Care. *Milbank Q*. 2021 Jun;99(2):519–  
544 41.
- 545 29. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-  
546 CoV-2 reinfection. *Nat Med*. 2022 Nov;28(11):2398–405.
- 547 30. Doll MK, Waghmare A, Heit A, Levenson Shakoor B, Kimball LE, Ozbek N, et al.  
548 Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During  
549 Delta vs Omicron Waves. *JAMA Network Open*. 2023 Feb 28;6(2):e231181.
- 550 31. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and  
551 depression in COVID-19 survivors: Role of inflammatory and clinical predictors. *Brain*  
552 *Behav Immun*. 2020 Oct;89:594–600.
- 553 32. Postolache TT, Benros ME, Brenner LA. Targetable Biological Mechanisms  
554 Implicated in Emergent Psychiatric Conditions Associated With SARS-CoV-2 Infection.

- 555 JAMA Psychiatry. 2020 Jul 31;
- 556 33. Villalpando JMG, Forcelledo HA, Castillo JLB, Sastré AJ, Rojop IEJ, Hernández  
557 VO, et al. COVID-19, Long COVID Syndrome, and Mental Health Sequelae in a Mexican  
558 Population. *Int J Environ Res Public Health*. 2022 Jun 7;19(12):6970.
- 559 34. Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al.  
560 Distinguishing features of Long COVID identified through immune profiling [Internet].  
561 medRxiv; 2022 [cited 2023 Jul 4]. p. 2022.08.09.22278592. Available from:  
562 <https://www.medrxiv.org/content/10.1101/2022.08.09.22278592v1>
- 563 35. PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation  
564 profiling of long COVID and association with 1-year recovery following hospitalisation in  
565 the UK: a prospective observational study. *Lancet Respir Med*. 2022 Aug;10(8):761–75.
- 566 36. Yavropoulou MP, Tsokos GC, Chrousos GP, Sfrikakis PP. Protracted stress-  
567 induced hypocortisolemia may account for the clinical and immune manifestations of Long  
568 COVID. *Clin Immunol*. 2022 Dec;245:109133.
- 569 37. Hastie CE, Lowe DJ, McAuley A, Mills NL, Winter AJ, Black C, et al. Natural history  
570 of long-COVID in a nationwide, population cohort study. *Nat Commun*. 2023 Jun  
571 13;14(1):3504.
- 572 38. Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19  
573 vaccination on long covid: systematic review. *BMJ Medicine* [Internet]. 2023 Feb 1 [cited  
574 2023 Jul 4];2(1). Available from: <https://bmjmedicine.bmj.com/content/2/1/e000385>
- 575 39. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F,  
576 et al. Trajectory of long covid symptoms after covid-19 vaccination: community based  
577 cohort study. *BMJ*. 2022 May 18;377:e069676.
- 578 40. Tsuchida T, Hirose M, Inoue Y, Kunishima H, Otsubo T, Matsuda T. Relationship  
579 between changes in symptoms and antibody titers after a single vaccination in patients



- 580 with Long COVID. *J Med Virol*. 2022 Jul;94(7):3416–20.
- 581 41. Bello-Chavolla OY, Antonio-Villa NE, Fernández-Chirino L, Guerra EC, Fermín-  
582 Martínez CA, Márquez-Salinas A, et al. Diagnostic performance and clinical implications of  
583 rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19  
584 registry data. *PLOS ONE*. 2021 Aug 31;16(8):e0256447.
- 585 42. Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A, Fermín-Martínez CA,  
586 Márquez-Salinas A, Bahena-López JP. Profiling Cases With Nonrespiratory Symptoms  
587 and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections in  
588 Mexico City. *Clin Infect Dis*. 2021 May 18;72(10):e655–8.
- 589 43. Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, et al.  
590 Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac  
591 in healthy adolescents. *Nat Commun*. 2022 Jun 28;13(1):3700.
- 592 44. Fonseca MHG, Pinto ACMD, Silva MFS, de Melo ACL, Vasconcelos GS, dos  
593 Santos ER, et al. Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by  
594 Booster Dose of BNT162b2 Vaccine. *Emerg Infect Dis*. 2022 Jun;28(6):1237–40.
- 595
- 596

597 **TABLES**

598 **TABLE 1.** Sociodemographic and clinical characteristics of individuals with post-acute  
599 sequelae of SARS-CoV-2 symptoms (PASC) as defined by the World Health Organization  
600 compared individuals without PASC and previously diagnosed with COVID-19 in the  
601 ENSANUT 2022 sample.


Characteristic	Overall Sample			
	Overall, N = 5,211 <sup>1</sup>	PACS indeterminate, N = 4,161 <sup>1</sup>	PACS positive, N = 1,050 <sup>1</sup>	p-value <sup>2</sup>
<b>Male sex (%)</b>	2,322 (45%)	1,934 (46%)	388 (37%)	<0.001
<b>Age (years)</b>	43 (31, 55)	42 (30, 54)	47 (35, 57)	<0.001
<b>Reinfection (%)</b>	638 (12%)	465 (11%)	173 (16%)	<0.001
<b>Omicron variant (%)</b>	2,087 (40%)	1,716 (41%)	371 (35%)	<0.001
<b>COVID-19 vaccine (%)</b>	4,830 (93%)	3,843 (92%)	987 (94%)	0.068
<b>Symptom duration</b>				<0.001
<1 month	1,363 (47%)	1,363 (74%)	0 (0%)	
1-3 months	478 (17%)	478 (26%)	0 (0%)	
3-6 months	124 (4.3%)	0 (0%)	124 (12%)	
>6 months	126 (4.4%)	0 (0%)	126 (12%)	
Still persistent	800 (28%)	0 (0%)	800 (76%)	
<b>Any symptom (%)</b>	2,839 (54%)	1,793 (43%)	1,046 (100%)	<0.001
<b>Loss of smell/taste (%)</b>	692 (13%)	501 (12%)	191 (18%)	<0.001
<b>Brain fog (%)</b>	166 (3.2%)	74 (1.8%)	92 (8.8%)	<0.001
<b>Gastrointestinal symptoms (%)</b>	160 (3.1%)	119 (2.9%)	41 (3.9%)	0.079
<b>Chest pain (%)</b>	285 (5.5%)	170 (4.1%)	115 (11%)	<0.001
<b>Breathlessness (%)</b>	358 (6.9%)	198 (4.8%)	160 (15%)	<0.001
<b>Dyspnea (%)</b>	513 (9.8%)	283 (6.8%)	230 (22%)	<0.001
<b>Musculoskeletal pain (%)</b>	913 (18%)	617 (15%)	296 (28%)	<0.001
<b>Dizziness (%)</b>	213 (4.1%)	130 (3.1%)	83 (7.9%)	<0.001
<b>Headache (%)</b>	817 (16%)	575 (14%)	242 (23%)	<0.001
<b>Weight loss (%)</b>	203 (3.9%)	149 (3.6%)	54 (5.1%)	0.019
<b>Loss of appetite (%)</b>	210 (4.0%)	169 (4.1%)	41 (3.9%)	0.8
<b>Kidney problems (%)</b>	55 (1.1%)	30 (0.7%)	25 (2.4%)	<0.001
<b>Sleep disturbances (%)</b>	288 (5.5%)	169 (4.1%)	119 (11%)	<0.001
<b>Fever (%)</b>	670 (13%)	608 (15%)	62 (5.9%)	<0.001
<b>Depression (%)</b>	187 (3.6%)	117 (2.8%)	70 (6.7%)	<0.001
<b>Anxiety (%)</b>	256 (4.9%)	145 (3.5%)	111 (11%)	<0.001
<b>Fatigue (%)</b>	1,250 (24%)	783 (19%)	467 (44%)	<0.001
<b>Chronic cough (%)</b>	978 (19%)	737 (18%)	241 (23%)	<0.001
<b>Post-exertional malaise (%)</b>	541 (10%)	342 (8.2%)	199 (19%)	<0.001
<b>PASC score</b>	0.0 (0.0, 5.0)	0.0 (0.0, 4.0)	3.0 (1.0, 8.0)	<0.001
<b>DISLI quartile</b>				<0.001
Q1	1,707 (33%)	1,430 (34%)	277 (26%)	
Q2	1,630 (31%)	1,304 (31%)	326 (31%)	
Q3	965 (19%)	721 (17%)	244 (23%)	
Q4	909 (17%)	706 (17%)	203 (19%)	
<b>CES-D score</b>	5.0 (3.0, 8.0)	5.0 (3.0, 7.0)	6.0 (4.0, 9.0)	<0.001
<b>Diabetes (%)</b>	358 (14%)	258 (13%)	100 (17%)	0.015
<b>Hypertension (%)</b>	505 (20%)	357 (18%)	148 (26%)	<0.001
<b>Daily smoking (%)</b>	178 (7.1%)	140 (7.3%)	38 (6.6%)	0.6
<b>Vaccine type</b>				0.091
Unvaccinated	381 (7.3%)	318 (7.6%)	63 (6.0%)	
mRNA	1,607 (31%)	1,291 (31%)	316 (30%)	

Characteristic	Overall Sample			p-value <sup>2</sup>
	Overall, N = 5,211 <sup>1</sup>	PACS indeterminate, N = 4,161 <sup>1</sup>	PACS positive, N = 1,050 <sup>1</sup>	
Adenovirus vector	2,629 (50%)	2,075 (50%)	554 (53%)	
Inactivated virus	438 (8.4%)	344 (8.3%)	94 (9.0%)	
Other	156 (3.0%)	133 (3.2%)	23 (2.2%)	
<b>Incapacitating symptoms</b>	457 (8.8%)	310 (7.5%)	147 (14%)	<0.001

<sup>1</sup>n (%); Median (IQR)

<sup>2</sup>Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test


**FIGURES**



603  
 604 **Figure 1.** Prevalence of persistent COVID-19 symptoms amongst SARS-CoV-2 N-protein seropositive adults  $\geq 20$  years in ENSANUT  
 605 2022 **(A)** and prevalence of post-acute sequelae of SARS-CoV-2 symptoms (PASC) as identified by a PASC score  $\geq 12$  in the overall  
 606 population, in SARS-CoV-2 N-protein seropositive adults and in individuals with COVID-19 previously diagnosed by a physician in the  
 607 ENSANUT 2022 sample **(B)**.


608

609




610

611 **Figure 2.** Prevalence of post-acute sequelae of SARS-CoV-2 symptoms (PASC) as  
 612 identified by a PASC score  $\geq 12$  stratified by geographical regions in Mexico within the  
 613 ENSANUT 2022 sample of adults  $\geq 20$  years (A). The figure also shows PASC prevalence  
 614 stratified by age and sex categories (B), by predominant circulating variant at the time of  
 615 last SARS-CoV-2 infection and vaccination status (C), by density-independent social lag  
 616 index (DISLI) quartiles in rural vs. urban setting (D), and in subjects with primoinfection  
 617 compared to at least one SARS-CoV-2 reinfection during periods of non-Omicron and  
 618 Omicron variant predominance (E).



621 **FIGURE 3.** Fixed effects logistic regression model adjusted by survey weights for prediction of post-acute sequelae of SARS-CoV-2  
 622 symptoms (PASC) identified by a PASC score  $\geq 12$  (A) and the presence of any persistent COVID-19 symptom (B) amongst Mexican  
 623 adults enrolled in ENSANUT 2022. Abbreviations: DISLI, Density-independent social lag-index; Depressive symptoms: Moderate to  
 624 severe depressive symptoms identified by the Center for Epidemiologic Studies Depression Scale.



625

626 **FIGURE 4.** Prevalence of incapacitating symptoms amongst patients with persistent post-  
 627 COVID-19 sequelae disaggregated by PASC scores using a 12-point threshold (A). The  
 628 figure also shows a fixed effects logistic regression model adjusted by survey weights for



629 prediction of debilitating PASC symptoms (**A**) and the presence of any persistent COVID-  
630 19 symptom (**B**) amongst Mexican adults enrolled in ENSANUT 2022. Abbreviations:  
631 PASC, Post-acute sequelae of SARS-CoV-2 infection; DISLI, Density-independent social  
632 lag-index; Depressive symptoms: Moderate to severe depressive symptoms identified by  
633 the Center for Epidemiologic Studies Depression Scale.  
634